TACE Combined with Percutaneous Microwave Coagulation Therapy Improves Long-Term Survival for Massive Hepatocellular Carcinomas
Long-term survival in patients with massive hepatocellular carcinomas (MHCC) was improved when treatment consisted of transcatheter arterial chemoembolization (TACE) combined with percutaneous microwave coagulation therapy (PMCT) compared with TACE alone, according to a study publishes in Cancer Management and Research.
This retrospective study include 102 patients with MHCC who were admitted to the Second Hospital of Nanjing from September 2010 to August 2015. There were 84 males (82.4%) and 18 females (17.6%) included, with a mean age of 52.45 years (range, 24 – 78 years).
The median time between treatment and overall survival (OS) was analyzed with log-rank tests. A multivariate analysis was done using the Cox regression model.
In the palliative group, TACE group, and TACE-PMCT group, median survival time was 3 months (range, 1–10 months), 3 months (range, 1–39 months), and 7.5 months (range, 3–30 months) (P = 0.038), respectively. In the palliative group, overall survival rates were 15 % at 6 months, 0% at 12 months, and 0% at 18 months. In the TACE group, overall survival rates were 30% at 6 months, 25.63% at 12 months, and 17.97% at 18 months. In the TACE-PMCT, overall survival rates were 50% at 6 months, 41.67% at 12 months, and 16.67% at 18 months (P = 0.0467).
There was a correlation between TACE sessions and survival time (rho = 0.462, P < 0.001). TACE treatments >3 (HR = 0.145, P < 0.001) was an independent predictor of the survival.
“TACE following PMCT is a safe and efficient treatment strategy in MHCC patients,” the authors concluded. “In addition, multiple TACE treatments should be considered as an alternative treatment therapies for the unresectable MHCC. However, the results of this retrospective study need to amplify the sample to identify the benefits from TACE–PMCT treatments and be validated by prospective clinical trial.”
Wei Y, Dai F, Zhao T, et al. Transcatheter arterial chemoembolization monotherapy vs combined transcatheter arterial chemoembolization-percutaneous microwave coagulation therapy for massive hepatocellular carcinoma (≥10 cm). Cancer Manag Res. 2018;10:5273-5282. doi: 10.2147/CMAR.S172395. eCollection 2018.